Champions Oncology (CSBR) Revenue (2010 - 2026)
Champions Oncology (CSBR) posted quarterly Revenue of $13.8 million for Q2 2026, up 11.98% year-over-year from $12.4 million in Q2 2025, and down 16.45% quarter-over-quarter from $16.6 million in Q1 2026.
Champions Oncology (CSBR) Revenue (2010 - 2026) Analysis & Trends
Champions Oncology's Revenue history runs 17 years deep, the most recent figure standing at $13.8 million for Q2 2026.
- In Q2 2026, Revenue rose 11.98% year-over-year to $13.8 million; the TTM figure through Apr 2026 stood at $59.4 million (up 4.36% YoY), while the FY2026 annual figure was $59.4 million, up 4.36% from the prior year.
- Revenue for Q2 2026 stood at $13.8 million, down from $16.6 million in the prior quarter.
- The five-year high for Revenue was $17.0 million in Q1 2025, with the low at $11.6 million in Q4 2023.
- The 5-year median for Revenue is $13.6 million (2022), against an average of $13.7 million.
- The sharpest annual moves came in 2023 and 2025: Revenue slipped 18.96% in 2023, then soared 41.77% in 2025.
- Champions Oncology's Revenue stood at $14.3 million in 2022, then retreated by 18.96% to $11.6 million in 2023, then climbed by 16.56% to $13.5 million in 2024, then grew by 11.46% to $15.0 million in 2025, then declined by 7.98% to $13.8 million in 2026.
- Business Quant data shows CSBR's Revenue at $13.8 million in Q2 2026, $16.6 million in Q1 2026, and $15.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn | 13.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 13.84 Mn |
| Jan 31, 2026 | 16.56 Mn |
| Oct 31, 2025 | 15.04 Mn |
| Jul 31, 2025 | 14.00 Mn |
| Apr 30, 2025 | 12.36 Mn |
| Jan 31, 2025 | 17.04 Mn |
| Oct 31, 2024 | 13.49 Mn |
| Jul 31, 2024 | 14.06 Mn |
| Apr 30, 2024 | 14.00 Mn |
| Jan 31, 2024 | 12.02 Mn |
| Oct 31, 2023 | 11.57 Mn |
| Jul 31, 2023 | 12.56 Mn |
| Apr 30, 2023 | 13.07 Mn |
| Jan 31, 2023 | 12.77 Mn |
| Oct 31, 2022 | 14.28 Mn |
| Jul 31, 2022 | 13.75 Mn |
| Apr 30, 2022 | 12.88 Mn |
| Jan 31, 2022 | 13.19 Mn |
| Oct 31, 2021 | 11.79 Mn |
| Jul 31, 2021 | 11.25 Mn |